LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

LLY

1,014.1

-1.68%↓

JNJ

240.68

+0.23%↑

ABBV

220

-2.15%↓

NVS

159.69

+0.31%↑

MRK

118.72

+1.06%↑

Kodu・Aktsiate loetelu・CorMedix Inc

CorMedix Inc

Avatud

SektorTervishoid

7.47 -2.73

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.38

Max

7.7

Põhinäitajad
By Trading Economics
Sissetulek	89M 109M
Müük	65M 104M
P/E Sektori keskmine	3.43 121.746
Kasumimarginaal	104.112
Töötajad	64
EBITDA	37M 57M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+80.34% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-271M 597M
Eelmine avamishind	10.2
Eelmine sulgemishind	7.47

Uudiste sentiment

By Acuity

64%

36%

299 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

9.2 / N/A Toetus ja vastupanu

CorMedix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. veebr 2026, 23:26 UTC

Suurimad hinnamuutused turgudel

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10. veebr 2026, 22:31 UTC

Tulu

Correction to America Movil 4Q Profit Article

10. veebr 2026, 22:22 UTC

Tulu

America Movil 4Q Profit Jumps on Lower Financial Costs

10. veebr 2026, 23:51 UTC

Market Talk

Tulu

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10. veebr 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10. veebr 2026, 23:40 UTC

Market Talk

Tulu

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10. veebr 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10. veebr 2026, 22:15 UTC

Tulu

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10. veebr 2026, 22:01 UTC

Tulu

Intact Financial 4Q EPS C$5.24 >IFC.T

10. veebr 2026, 21:54 UTC

Tulu

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10. veebr 2026, 21:53 UTC

Tulu

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10. veebr 2026, 21:51 UTC

Tulu

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10. veebr 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q EPS 12c >JHX

10. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q Adj EPS 24c >JHX

10. veebr 2026, 21:49 UTC

Tulu

James Hardie Industries 3Q Sales $1.24B >JHX

10. veebr 2026, 21:49 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10. veebr 2026, 21:48 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10. veebr 2026, 21:47 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Võrdlus sarnastega

Hinnamuutus

CorMedix Inc Prognoos

Hinnasiht

By TipRanks

80.34% tõus

12 kuu keskmine prognoos

Keskmine 13.67 USD 80.34%

Kõrge 15 USD

Madal 13 USD

Põhineb 4 Wall Streeti analüütiku instrumendi CorMedix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi CorMedix Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.2 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

299 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.